Skip to main content
. 2021 Jan 22;13(3):419. doi: 10.3390/cancers13030419

Figure 3.

Figure 3

Effect of synthetic cannabinoids WIN55,212-2 or JWH133 on the viability and morphology of glioblastoma cells (a,b) and normal human astrocytes (c,d). (a,c) Cell viability was determined 24 h and 48 h after exposure to cannabinoids using MTT metabolism test. Results are expressed in values relative to DMSO-treated control cells, as the mean ± SEM of at least three independent experiments (each in triplicate). (b,d) Phase-contrast micrographs show control glioblastoma cells and normal human astrocytes (treated with 0.1% DMSO) with a flattened appearance and typical changes in cellular morphology after 36 h—exposure to 15 µM WIN55,212-2 or 10 µM JWH133. Note the retraction of cell extensions, cell shrinkage, cell membrane blebbing, and the formation of apoptotic bodies upon exposure to cannabinoids, as well as extensive cytoplasm vacuolization in WIN55,212-2-treated cells. Scale bars correspond to 40 µm in T3, T10 cells, and astrocytes, and to 20 µm in established glioma cell lines.